UBS analysts shake up ratings of European drugmakers

  • UBS downgrades AstraZeneca and upgrades GSK
  • UBS also upgrades Novartis and Sanofi, and downgrades Novo Nordisk
  • Sector valuations are not demanding, except for Novo Nordisk
  • UBS forecasts strong sales for GSK’s Shingrix
  • UBS is positive on Novartis’ cancer, chronic spontaneous urticaria, and MS drugs
  • Concerns about AstraZeneca’s exposure to Medicare Part D reform
  • AstraZeneca shares slumped 3% in London

UBS analysts have made significant changes to their ratings of European drugmakers. They have downgraded AstraZeneca from buy to sell, while upgrading GSK from sell to buy. Additionally, UBS has upgraded Novartis and Sanofi to buy from neutral, and downgraded Novo Nordisk to neutral from sell. The analysts believe that sector valuations are reasonable, except for Novo Nordisk. They also forecast strong sales for GSK’s Shingrix, and have a positive outlook on Novartis’ cancer, chronic spontaneous urticaria, and MS drugs. However, they express concerns about AstraZeneca’s exposure to Medicare Part D reform. As a result of the downgrades, AstraZeneca shares slumped 3% in London.

Public Companies: AstraZeneca (AZN), GSK (GSK), Novartis (NOVN), Sanofi (SAN), Novo Nordisk (NOVO.B)
Private Companies:
Key People: Matthew Weston (Analyst)

Track all markets on TradingView

Factuality Level: 7
Justification: The article provides information about UBS analysts’ ratings of European drugmakers, including downgrades and upgrades. It mentions the reasons behind the changes in ratings and provides some analysis on the sector valuations and specific drugs. However, the article lacks in-depth analysis and does not provide a comprehensive view of the topic.

Noise Level: 3
Justification: The article provides information on UBS analysts’ ratings of European drugmakers and their reasoning behind the changes. It mentions the specific upgrades and downgrades for each company and provides some insight into the analysts’ concerns and expectations. However, the article is quite short and lacks in-depth analysis or supporting evidence for the ratings. It also includes some irrelevant information about text-to-speech technology and a request for feedback.

Financial Relevance: Yes
Financial Markets Impacted: European drugmakers

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses changes in ratings of European drugmakers by UBS analysts, which can impact the financial markets.

Reported publicly: www.marketwatch.com